Novo Nordisk Research Centre Oxford is an innovative target discovery
and translational research unit with a focus on identifying novel,
game-changing therapies for patients with type 2 diabetes and
We employ advanced computational biology, state-of-the-art
discovery screening technologies, genetics and human-centric cell
systems to dissect pathophysiology and identify novel drug targets.
The site is a fusion of the best of academia, biotech and big pharma
in order to realize cutting-edge biology and start a target’s
journey from bench to bedside.
NNRCO is one of our three transformational research units,
operating at the boundaries of frontier science with a mandate to
find dynamic, agile and distinctive new ways of working to diversify
the company’s pipeline with disruptive medicines.